CAMBRIDGE, Mass. — August 5, 2025 — Leads & Copy — Beam Therapeutics Inc. (Nasdaq: BEAM) reported its second quarter 2025 financial results and provided an update on its clinical development progress for BEAM-302 in alpha-1 antitrypsin deficiency (AATD). The company also reiterated its corporate and pipeline progress across its hematology and genetic disease franchises.
According to Beam, 17 patients have been dosed in the Phase 1/2 trial of BEAM-302, which continues to demonstrate a durable correction of the disease-causing mutation, restoration of AAT physiology, and a well-tolerated safety profile. The company has expanded dose exploration in Part A and has initiated enrollment in Part B of the trial. Data from both parts of the Phase 1/2 trial and a clinical development update are expected in early 2026.
Dosing has been completed for 30 sickle cell disease patients, and the first adolescent patient has been dosed in the BEACON Phase 1/2 trial of BEAM-101. Updated data is expected by the end of 2025.
The company ended the second quarter of 2025 with $1.2 billion in cash, cash equivalents, and marketable securities, with the cash runway expected to support operating plans into 2028.
John Evans, chief executive officer at Beam, said the company made significant clinical, operational, and regulatory progress across each of its high-priority programs in the first half of 2025. He added that the company aims to harness this momentum heading into key catalysts at the end of 2025 and early next year.
Contacts:
Investors: Holly Manning, Beam Therapeutics, hmanning@beamtx.com
Media: Josie Butler, 1AB, josie@1abmedia.com
Source: Beam Therapeutics
